This site is intended for Healthcare Professionals only.

Zydus Cadila gets regulator nod to market its generic cancer drug in US


Share post:

Drug maker Zydus Cadila today (June 25) received an approval from the US health regulator to market Pemetrexed injection in the American market.

Pemetrexed is used to treat certain kinds of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that helps in slowing or stopping the growth of cancer cells.

The firm got nod from the US Food and Drug Administration (USFDA) for the injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials, it said in a statement.

The approved drug will be produced at the formulation manufacturing facility at Ahmedabad in India, the company said.

Zydus Cadila now has 319 approvals.

Since 2003-04, the company has filed over 400 abbreviated new drug applications (ANDAs).

The company discovers, develops, manufactures, and markets a broad range of healthcare products. The group employs around 25,000 people worldwide.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

FIP supports PDA’s Safer Pharmacies Charter

PDA urges all UK pharmacists to take part in the 2024 Safer Pharmacies Survey The International Pharmaceutical Federation...

Topiramate should not be prescribed for epilepsy during pregnancy unless…

MHRA tightens safety measures for topiramate by introducing a new pregnancy prevention programme  Healthcare professionals in the UK are...

WHO issues alert on fake copies of Novo Nordisk’s diabetes drug Ozempic

Falsified batches of Ozempic (semaglutide) were detected in Brazil, the UK, Northern Ireland and the United States The...

Synnovis cyber attack: NHS patient data leaked, services impacted

The NHS has set up helpline number to answer queries and concerns about patient data as Synnovis cyber...